Medical termination of pregnancy from day 85 to day 153 of gestation: A randomized comparison between administration of the initial dose of misoprostol at home or in the clinic

5.1 Risk mitigation plan

For safety reasons no patient should be alone at home when taking the first dose of misoprostol. Women who have already developed regular contractions should not administer misoprostol at home.

7.1 Primary objective

To investigate the proportion of women who are successfully treated as day-care patients (day-care being defined as 9 hours from time of admission).

7.2 Secondary objectives

The two groups will also be compared regarding difference in length of stay in the hospital (h) (from admittance to the in-patient unit until discharge) and success rate at 24 h (success will be defined as the expulsion of the foetus), difference in the induction-to-abortion interval (defined as the time from the first dose of Misoprostol until the expulsion of the foetus) (mean/median), doses of Misoprostol used (mean/median), frequency of complications (direct and up to 4 weeks), surgical interventions needed (such as evacuation rates) and side effects experienced. Patient satisfaction will be compared between the groups using pretested questions.

10.1 Interventions and controls

Women requesting a termination of pregnancy (at 85 – 153 days of gestation) will be randomized into two groups:

Group 1) Administration of 4 tablets of 0,2 mg of Misoprostol vaginally by the patient herself at home before presenting in the inpatient unit 2 hours later.

Group 2) Administration of 4 tablets of 0,2 mg of Misoprostol vaginally after admission to the inpatient unit.

After administration of the first dose of Misoprostol women in both groups will be treated according to the clinical routine protocol (see below). A follow-up will be undertaken two to four weeks after discharge.

11.1 Main outcome measure

The proportion of women who are successfully treated as day-care patients will be the main outcome (day-care being defined as 9 hours from time of admission).

11.2 Secondary outcome measures

Secondary outcome measures will include the difference in time spent in hospital (h), the difference in the induction-to-abortion interval (defined as the time (min) from the first dose of Misoprostol until the expulsion of the foetus) (mean/median), the success rate of the termination of pregnancy at 24 hours (success will be defined as the expulsion of the foetus), and doses of Misoprostol used (mean/median). The difference in frequency of complications (during treatment and until the follow-up visit), the difference regarding surgical interventions for incomplete or retained placenta (evacuation rates) and side effects will be measured. Other outcome measures will be time for and grade of maximal pain during the abortion and maximal pain measured on a VAS (visual analogue scale) (before and 30 minutes following administration of pain treatment) and doses of pain medication given. Acceptability with allocated treatment (evaluated by two pretested questions) and the difference in number of women who need to be admitted to the hospital earlier prior to planned admission and for which reasons will be registered.

12.1 Inclusion criteria

Women aged >/= 18 years requesting a termination of pregnancy, for social, medical or foetal indications and the gestational age being determined to 85 – 153 days (with ultrasonography), willing and able to understand and participate after the study has been explained, with good understanding of Swedish or English language, in general good health, with a single intra-uterine pregnancy, who have given their informed consent will be eligible for the study.

12.2 Exclusion criteria

Women who do not wish to participate or who are unable to communicate in Swedish or English. Women carrying a non-viable pregnancy (confirmed by ultrasonography).

Women with a history or evidence of disorders that represent a contraindication to the use of Mifepristone or Misoprostol (adrenal pathology, steroid dependent cancer, porphyria, known allergy to the medication).

Women with pre-existing health conditions for whom the execution of a medical abortion as judged by the investigator could compromise their condition will also be excluded. Examples of health conditions of concern are: severe anaemia, severe asthma, haemorrhagic disorders, treatment with anticoagulants or corticoids, severe cardiac disease or hypertension, severe liver disease, severe kidney disease or severe psychiatric disorders.

Fetal malformation that may impact time–to-expulsion (such as hydrocephalus, hydrops/edema) or a duplex pregnancy.

13.1 Enrolment

All eligible women, requesting a termination of pregnancy, with live pregnancies from day 85 to day 153 of gestation, will be invited to participate in the study at the initial outpatient consultation. The women will receive detailed oral and written information and have the possibility to ask questions regarding the study according to ICH-GCP. Written informed consent will be signed by the attending physician and the women before randomization.

13.2 Allocation and treatment

Designated study nurses and doctors will be responsible for recruiting and examining study participants at the outpatient clinic. A medical history will be obtained to identify contraindications and risk factors or complications to the pregnancy. The history of the woman will include personal and family history of relevant diseases, current use of medications, allergies, obstetric and gynaecological history or any bleeding tendencies.

Physical examination will be performed including vaginal examination and ultrasonography to establish the gestational age. All women will be screened for bacterial vaginosis and Chlamydia infection and treated if positive. Vital signs (pulse, blood pressure), length, weight, haemoglobin, blood group and Rhesus typing will be documented by the assisting nurse or midwife.

Eligible women with a pregnancy from day 85 to day 153 of gestation who wish to participate in the study and who sign an informed consent will be randomized into either Group 1 or 2:

After randomization, all women will swallow Mifepristone 200 mg at the outpatient clinic. The day when Mifepristone is administered counts as Day 1. The woman will receive the date and time when she shall return to the inpatient unit to continue the treatment. The time interval between the administration of Mifepristone and Misoprostol is 36-48 hours according to national guidelines.

On Day 3 the woman will administer Misoprostol:

Group 1) Administration of 4 tablets of 0, 2 mg of Misoprostol vaginally by the patient herself at home before admission to the inpatient unit two hours later.

or

Group 2) Administration of 4 tablets of 0, 2 mg of Misoprostol vaginally after arrival to the inpatient unit.

When admitted to the inpatient unit the women will follow the clinical protocol which means that if she does not abort within 3 hours of the first vaginal dose of Misoprostol she will receive a second dose of 2 tablets of 0,2 mg Misoprostol sublingually and then every 3^rd hour until expulsion of the foetus (maximum of 4 doses).

Pain medication will be administered as NSAIDs and Paracetamol which will be administered every eight hours. Oxikodon 5 mg (orally) and/or Morphine 5 mg (injectable) will be administered as required. Other analgesic options are transcutaneous electrical nerve stimulation (TENS), paracervical blockade (PCB) with Carbocain-Adrenalin or epidural anaesthesia.

After the abortion the women should be observed in the hospital for a minimum of 1 hour to monitor the vital signs and the amount of vaginal bleeding. Reasons for staying longer than the clinical routine will be documented. Before being discharged the woman will be asked regarding pain, satisfaction with the treatment and experienced side effects.

After being discharged the woman is recommended to contact the clinic if heavy vaginal bleeding, severe abdominal pain (where prescribed analgesic do not reduce the pain), malaise or fever >38 °C should occur. The woman will be booked for a follow-up with a midwife 2 - 4 weeks after discharge from the ward. Since previous studies have shown that the loss for the follow-up visit may be as high as 20 %, the follow-up could also be conducted by telephone-call or e-mail to reach as many women as possible. The follow-up a will cover contraceptive plan (possible insertion of an IUD (intra-uterine device)) or birth control implant (if not already done) and any extra visits or complications since discharge. If the reason for termination of pregnancy was a foetal malformation, the patient will also be booked to the referring obstetrician.

The initial judgment about the outcome of medical abortion is made at the clinic before discharge home. The outcome is classified on the basis of the woman’s history and the clinical findings, as one of the following:

1. Complete abortion - no additional treatment needed for foetal and complete placental expulsion - uterus empty

2. Incomplete abortion - vacuum aspiration or exeresis done due to remnants of tissue in uterus

The final outcome of the medical abortion will be assessed at the follow-up

13.3 Randomization procedure

The randomization ratio between intervention and control group will be 1:1 in permuted blocks of 4-12. Randomization will be performed by the midwife in the abortion clinic at the time of the first visit after the patient has been judged eligible for participation and has signed informed consent in the presence of the attending physician. Allocation to intervention or control will be performed via randomization through a study specific internet allocation site after an online checklist of inclusion and exclusion criteria has been completed. All women will be identified through a patient log with name and personal identification number and the randomization number (patient study ID). The randomization number will be used on all paper and eCRFs (case record form), for future identification. The study will for practical and ethical reasons not be blinded. The medical abortion will be performed according to the Swedish national guidelines.

13.4 Discontinuation

After recruitment, women may withdraw from the trial at any time without giving any reason if they do not wish to participate. If interim analysis shows that a higher rate of women (compared to what is previously known, up to 4%) included in the study will abort at home or on the way to the hospital the study will be interrupted as judged by the DSMB (11).

13.5 Discontinuation of the study itself

The regimen for medical abortion that will be used in the study is well known. Medical abortion when started can not be interrupted since no other abortion methods are available for second trimester abortions in Sweden. If a woman regret the decision to terminate the pregnancy she can interrupt the abortion, and the local clinical protocol will be used. The proposed regimen is the one recommended by SFOG (Svensk Förening för Obstetric och Gynekologi). Thus a discontinuation of the study is not anticipated based on any known incidence of SAE or any other reasons.

14.1 Adverse events

Definition: An adverse event (AE) is defined as any untoward medical occurrence in a patient (or clinical investigation subject) administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including abnormal lab finding), symptom, or disease temporarily associated with the use of a medical product, whether or not considered related to this medical product.

A Serious AE (SAE) is defined as any event that:

• results in death

• is life threatening

• results in hospitalization or prolonged stay in hospital

• results in temporary or permanent morbidity

• results in congenital malformation/teratogenic effect

• Any other serious event

All adverse events will be reported by staff in the patient chart or self-reported by the patient in the questionnaires. All reported adverse events will be recorded in the patient records and scrutinized by the investigator and monitor to judge the severity (mild, moderate, severe) and relation to treatment (not related, possibly related, probably related).

All serious adverse events will be reported by the sponsor to the Medical Products Agency on paper for subsequent registration into the EudraVigilance database.

14.2 Reporting of AE, SAE and SUSARs

• All patients will be asked for adverse events at every visit/contact with the investigator or study nurse/midwife with the exception for what is mentioned under 13.1

• Adverse events will be reported irrespective if the event has any relation with the study drug or not

• All Adverse events must be recorded in the CRF, defining the relationship to study medication, severity and seriousness. Adverse Events should also be recorded in the patient records if applicable

• If a reported SAE is present when the patient completes the study the event must be followed for up to three months past the final visit or followed until final outcome is known or the condition is stable

• AE/SAE will be registered until the end of the study

14.3 Reporting of SAE and SADE and USADE

Any SAE that might have led to a SAE if: a) suitable action had not been taken or b) intervention had not been made or c) if circumstances had been less fortunate and in addition new findings/updates in relation to already reported events must be reported to the sponsor on a separate SAE report form within 24 hours of the initial notification of the event-for device deficiencies regulatory requirement is within 3 days-however, a 24 hour period will be maintained for all serious adverse events in this trial.

• The initial notification to the sponsor can be made on a SAE-report form, by e-mail or telephone.

• At the time of initial reporting the investigator must provide a minimum requirement, the patient number, birth date, description of the SAE and a preliminary assessment of causality.

• Supplemental information shall be reported by the investigator to the sponsor as soon as possible. If the SAE is fatal or life-threatening the investigator is responsible to report follow-up information to the sponsor within 5 days after the initial report

• For all reportable events as described above which indicate an imminent risk of death, serious injury, or serious illness and that requires prompt remedial action for other patients/subjects, users or other persons or a new finding to it: immediately, but not later than 2 calendar days after awareness by sponsor of a new reportable event or of new information in relation with an already reported event.

• Any other reportable events as described above or a new finding/update to it: immediately, but not later than 7 calendar days following the date of awareness by the sponsor of the new reportable event or of new information in relation with an already reported event.

14.5 Reporting SUSAR

14.6 Annual Safety Report

The sponsor will assemble the annual safety report according to the instruction of the Medical Product Agency.

16.1 Sample size

The main outcome measure will be the difference in the proportion (%) of women who are treated as day care patients between the two groups. A difference of 10 percent could be regarded as clinically significant.

784 patients (392 per group) are required to have a 90% chance of detecting, as significant at the 5% level (2-sided test), an increase in the primary outcome measure from 70% in the control group to 80% in the experimental group. To compensate for loss to follow-up 896 women will be recruited.

Patient flow during trial will follow the CONSORT chart. For demographic variables the full analysis set, FAS (all subjects randomized), will be presented with descriptive statistics. All subjects randomized having known primary outcome (day care treatment) will be included in the main efficacy analysis in their randomized groups. If attempts fail to locate and contact a woman lost to follow-up, and her final outcome of treatment is not known that woman will be excluded from the main analysis.

Crude rates for each outcome will be calculated in each arm and exact confidence intervals based on the binomial distribution calculated as described in Armitage and Berry (1994).

Comparisons of percentages, such as the difference in number of women being treated as day-care patients, will be calculated by chi²-test or Fischers exact test. Confidence intervals for differences between percentages will be calculated. Comparisons of differences in number of doses and cumulated dose of medication used and hours spent at hospital will be analysed by large sample statistical methods. VAS-scale and difference in patient satisfaction will be analysed by non-parametric rank-tests.

Results will be considered statistically significant if P-value < 0,05. Analyses will be carried out using SPSS (24.0) software package.

The groups will be compared regarding maternal age, parity, number of former abortions, gestational age, maternal BMI, smoking and reasons for termination of pregnancy.

18.1 Distribution and handling of the study drug

Misoprostol and mifepristone will be used according to the clinical routine.

The off label use is close to the approved use. Sublingual administration results in very similar effects to vaginal administration of misoprostol but drug absorption is not affected by vaginal bleeding. Vaginal misoprostol is approved as Medabon (SunPharma) but not available in Sweden.

The misoprostol tablets are packed in aluminium blisters. Each participating woman will get the mifepristone tablet to swallow in the abortion clinic after inclusion in the trial (Day 1). For women randomized to Group 1 misoprostol tablets for home use will be provided in the same way and the same dose as for home use in early medical abortion up to 9 weeks of gestation. Additional misoprostol will be provided to the participating woman after admission to the clinic until abortion as needed. Women randomized to Group 2 will receive misoprostol in the clinic.

18.2 Justification of the choice of misoprostol in the form of Cytotec instead of Medabon

The recommended dosage of misoprostol for medical abortion beyond 12 weeks and 0 days is a loading dose of 800 microgram of misoprostol administered 36 to 48 hours following mifepristone. This dosage is approved in Sweden for medical abortion up to 9 weeks (Medabon, combi pack) and investigated in Sweden for medical abortion at 9 to 22 weeks of gestation (Concept Foundation, EudraCT Number : 2013-004294-27, Dnr 5.1-2013-89810) multicenter trial) with repeat doses of 400 microgram misoprostol (using misoprostol tablets from Medabon combipacks) administered up to expulsion of the pregnancy.

Misoprostol in Medabon has been accepted as being equivalent in bioavailability of misoprostol free acid to misoprostol free acid in Cytotec. Since Medabon is no longer available on the Swedish market Cytotec replace Medabon in clinical practice. This implies that the benefit-risk balance of Cytotec in the study population is positive.

Monitoring

Before the study starts an external monitor, a research nurse/midwife (trained and familiar in ICH-GCP and independent of study conduct) will perform an initiation visits at each site to ensure that the essential documents and study records are stored and kept safe in Investigator files. Monitor will also discuss the details regarding the randomization procedure and to see to that staff is familiar with the concept of documenting according to ICH-GCP in medical records and in CRF. Monitor will also visit the site during the study regularly to conduct source data verification, and perform a visit after the study has ended to close the site and gather essential documents to sponsor. Upon request, the monitor, sponsor (auditor) and/or sponsor representative, medical authorities are entitled direct access to source data under the condition that there is a valid signed secrecy agreement. Source documents are considered e.g. patients medical records, ultra scan pictures and other relevant documents that contains data that verifies the accurateness and is stated in the approved protocol.

Declaration of End of Trial Notification will be sent to the MPA at the latest 90 days after EOT (or at premature discontinuation of the trial),